Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Retifanlimab FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma ESMO Launches Its Roadmap 2030 to Support Oncology Professionals and Foster Progress in Cancer Care MOST POPULAR High Sensitivity of Mismatch Repair–Deficient Locally Advanced Rectal Cancer to Single-Agent... June 8, 2022 Tattoo Ink May Show Up as Suspicious Spots in Lymph Nodes... July 9, 2021 Makeup Artist Gives Breast Cancer Survivors Free Makeovers January 6, 2021 Longer PFS in Patients with Advanced Melanoma Treated with TILs than... December 14, 2022 Load more HOT NEWS Running a cancer helpline in COVID-19: two years on the virtual... Some Brain Cells May Help to Fuel Cancer Metastasis ctDNA May Guide Who Needs Chemo After Colorectal Cancer Surgery Delivering the future of paediatric brain tumour therapy
